Literature DB >> 17558895

Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.

G Monego1, V Arena, N Maggiano, L Costarelli, A Crescenzi, G Zelano, M Amini, A Capelli, A Carbone.   

Abstract

Seventy-one cases that had resulted borderline for HER-2 protein expression at conventional immunohistochemical assay (2+) were assessed for HER-2 gene amplification by real-time PCR and by FISH in accordance with the manufacturer's recommendations (gene amplification with ratio >or=2 in both methods). Thirty-three out of 71 cases (47%) resulted amplified at real-time PCR analysis, whereas 15 cases resulted positive at FISH (21%). Apparently, PCR was more sensitive than FISH in HER-2 determination, only 10 cases resulting amplified in both tests. When the mean ratio value obtained in all PCR experiments was adopted as threshold in determining HER-2 gene amplification, the apparent sensitivity of PCR was reduced but correlation between PCR and FISH results was dramatically increased. Furthermore, when the mean PCR ratio value observed in the FISH-positive group was chosen as threshold, the best agreement between PCR and FISH results was achieved. Therefore, we found that the proposed threshold ratio value of >or=2 is not accurate in separating HER-2 amplified and non-amplified cases. We suggest that the threshold ratio value in PCR tests should be determined in each laboratory using FISH controlled cases. Finally, above certain in-lab generated threshold values, PCR might be proposed as a highly predictive positive test in HER-2 assessment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17558895     DOI: 10.1080/00365510601128934

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

1.  Detection of HER2 amplification in circulating free DNA in patients with breast cancer.

Authors:  K Page; N Hava; B Ward; J Brown; D S Guttery; C Ruangpratheep; K Blighe; A Sharma; R A Walker; R C Coombes; J A Shaw
Journal:  Br J Cancer       Date:  2011-03-22       Impact factor: 7.640

2.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

3.  SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Authors:  Jocelyne Jacquemier; Frédérique Spyratos; Benjamin Esterni; Marie-Joëlle Mozziconacci; Martine Antoine; Laurent Arnould; Sarab Lizard; Philippe Bertheau; Jacqueline Lehmann-Che; Cécile Blanc Fournier; Sophie Krieger; Frédéric Bibeau; Pierre-Jean Lamy; Marie Pierre Chenard; Michèle Legrain; Jean-Marc Guinebretière; Delphine Loussouarn; Gaëtan Macgrogan; Isabelle Hostein; Marie Christine Mathieu; Ludovic Lacroix; Alexander Valent; Yves Marie Robin; Françoise Revillion; Magali Lacroix Triki; Aline Seaume; Anne Vincent Salomon; Patricia de Cremoux; Geneviève Portefaix; Luc Xerri; Sophie Vacher; Ivan Bièche; Frédérique Penault-Llorca
Journal:  BMC Cancer       Date:  2013-07-22       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.